Over the past 12 months, 5 insiders at Athira Pharma, Inc. filed 5 open-market SEC Form 4 transactions on ATHA: 0 purchases worth $0 and 5 sales worth $43K. Insiders have been net sellers over this period. The most recent filing was on Jan 2, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 26 | Kevin ChurchCHIEF SCIENTIFIC OFFICER | SELL | 876 | $6.88 | $6K |
| Jan 2, 26 | Mark James LittonPresident and CEO | SELL | 2.6K | $6.88 | $18K |
| Jan 2, 26 | Robert RenningerChief Financial Officer | SELL | 297 | $6.88 | $2K |
| Jan 2, 26 | Martin Javier SanCHIEF MEDICAL OFFICER | SELL | 1.6K | $6.88 | $11K |
| Jan 2, 26 | Mark WorthingtonGeneral Counsel and CCO | SELL | 876 | $6.88 | $6K |
| Jul 1, 25 | Kevin ChurchCHIEF SCIENTIFIC OFFICER | SELL | 8.5K | $0.29 | $2K |
| Jul 1, 25 | Mark James LittonPresident and CEO | SELL | 25.1K | $0.29 | $7K |
| Jul 1, 25 | Robert RenningerSVP, Finance and Accounting | SELL | 2.9K | $0.29 | $840 |
| Jul 1, 25 | Martin Javier SanCHIEF MEDICAL OFFICER | SELL | 10.8K | $0.29 | $3K |
| Jul 1, 25 | Mark WorthingtonGeneral Counsel and CCO | SELL | 8.5K | $0.29 | $2K |
| Jan 2, 25 | Kevin ChurchCHIEF SCIENTIFIC OFFICER | SELL | 8.5K | $0.56 | $5K |
| Jan 2, 25 | Mark James LittonPresident and CEO | SELL | 25.1K | $0.56 | $14K |
| Jan 2, 25 | Robert RenningerVP of Finance | SELL | 2.9K | $0.56 | $2K |
| Jan 2, 25 | Martin Javier SanCHIEF MEDICAL OFFICER | SELL | 10.8K | $0.56 | $6K |
| Jan 2, 25 | Mark WorthingtonGeneral Counsel and CCO | SELL | 8.5K | $0.56 | $5K |
| Sep 5, 24 | Kevin ChurchCHIEF SCIENTIFIC OFFICER | SELL | 2.5K | $0.57 | $1K |
| Sep 5, 24 | Andrew GengosCFO and Chief Business Officer | SELL | 1.3K | $0.57 | $725 |
| Sep 5, 24 | Rachel LeningtonCOO and CDO | SELL | 2.5K | $0.57 | $1K |
| Sep 5, 24 | Mark James LittonPresident and CEO | SELL | 5.0K | $0.57 | $3K |
| Sep 5, 24 | Mark WorthingtonGENERAL COUNSEL | SELL | 2.5K | $0.57 | $1K |
| Jun 24, 24 | Kelly A RomanoDirector | BUY | 27.4K | $2.42 | $66K |
| Jun 21, 24 | Kelly A RomanoDirector | BUY | 15.0K | $2.26 | $34K |
| Jan 5, 24 | Kevin ChurchCHIEF SCIENTIFIC OFFICER | SELL | 2.4K | $2.91 | $7K |
| Jan 5, 24 | Andrew GengosCFO AND CHIEF BUSINESS OFFICER | SELL | 1.2K | $2.91 | $4K |
| Jan 5, 24 | Rachel LeningtonCOO AND CDO | SELL | 2.4K | $2.91 | $7K |
| Jan 5, 24 | Mark James LittonCEO | SELL | 4.8K | $2.91 | $14K |
| Jan 5, 24 | Mark WorthingtonGENERAL COUNSEL | SELL | 2.4K | $2.91 | $7K |
| Dec 29, 23 | Joseph EdelmanDirector,TenPercentOwner | BUY | 164.0K | $2.38 | $390K |
| Dec 28, 23 | Joseph EdelmanDirector,TenPercentOwner | BUY | 409.6K | $2.44 | $999K |
| Dec 27, 23 | Joseph EdelmanDirector,TenPercentOwner | BUY | 32.1K | $2.28 | $73K |
| Jun 7, 23 | Andrew GengosSee Below | BUY | 11.7K | $3.44 | $40K |
| Jun 5, 23 | Andrew GengosSee Below | BUY | 15.0K | $3.02 | $45K |
| Jun 2, 23 | Andrew GengosSee Below | BUY | 10.0K | $2.95 | $28K |
| Mar 30, 23 | Grant PickeringDirector | BUY | 15.0K | $2.47 | $37K |
| Mar 29, 23 | James A JohnsonDirector | BUY | 5.0K | $2.40 | $12K |
| Mar 29, 23 | Grant PickeringDirector | BUY | 10.0K | $2.33 | $23K |
| Jan 5, 23 | Kevin ChurchChief Scientific Officer | SELL | 2.4K | $2.91 | $7K |
| Jan 5, 23 | Andrew GengosSee Below | SELL | 1.2K | $2.91 | $4K |
| Dec 28, 22 | Glenna MilesonChief Financial Officer | BUY | 50.0K | $2.85 | $143K |
| Dec 2, 22 | Kelly A RomanoDirector | BUY | 30.0K | $3.29 | $99K |
| Nov 15, 22 | Hans MoebiusChief Medical Officer | BUY | 5.0K | $3.29 | $16K |
| Jun 30, 22 | Joseph EdelmanDirector,TenPercentOwner | BUY | 1.10M | $2.99 | $3.3M |
| Jun 29, 22 | Joseph EdelmanDirector,TenPercentOwner | BUY | 270.0K | $2.99 | $807K |
| Jun 28, 22 | Hans MoebiusChief Medical Officer | BUY | 10.0K | $2.88 | $29K |
| Jun 23, 22 | Kevin ChurchExecutive VP, Research | SELL | 2.6K | $2.69 | $7K |
| Jun 23, 22 | Rachel LeningtonChief Operating Officer | SELL | 4.2K | $2.69 | $11K |
| Jun 23, 22 | Mark James LittonChief Executive Officer | SELL | 8.0K | $2.69 | $21K |
| Jun 23, 22 | Glenna MilesonChief Financial Officer | SELL | 2.6K | $2.69 | $7K |
| Jun 23, 22 | Mark WorthingtonGeneral Counsel | SELL | 2.6K | $2.69 | $7K |
| Mar 31, 22 | Kelly A RomanoDirector | BUY | 8.0K | $13.11 | $105K |
Over the past 12 months, insiders at Athira Pharma, Inc. filed 0 open-market purchases worth $0 and 5 sales worth $43K on ATHA, which makes them net sellers over the period. The most recent Form 4 was filed on Jan 2, 26.
The largest recent open-market ATHA insider purchase in our data was $3.3M by Joseph Edelman, Director,TenPercentOwner, filed on Jun 30, 22.
5 different insiders at Athira Pharma, Inc. filed open-market SEC Form 4 transactions on ATHA over the last 12 months.
InsiderTape plots every ATHA insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Athira Pharma, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →